Clinical trial NCT04535986
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
Sponsor: Verona Pharma plc
Start date: 2020-09-29; Completion date: 2022-12-02
Enrollment: 763 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Detailed description:

Arms: arm 1: Ensifentrine Nebulized Suspension; 3 mg BID arm 2: Placebo Nebulized BID
Interventions: intervention 1: Ensifentrine intervention 2: Placebo
Intervention descriptions: intervention 1: Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks intervention 2: Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks

Protocol documents:
Prot_000.pdf: 













































































































































































































































































SAP_001.pdf: 






























































































































































































Signer Events
Signature
Timestamp
      Accepted: 12/7/2022 5:17:29 AM
      ID: a0329438-4184-4e0c-8f5d-0d1ced879e78
      Company Name: IQVIA
In Person Signer Events
Signature
Timestamp
Editor Delivery Events
Status
Timestamp
Agent Delivery Events
Status
Timestamp
Intermediary Delivery Events
Status
Timestamp
Certified Delivery Events
Status
Timestamp
Carbon Copy Events
Status
Timestamp
Witness Events
Signature
Timestamp
Notary Events
Signature
Timestamp
Envelope Summary Events
Status
Timestamps
Envelope Sent
Hashed/Encrypted
12/6/2022 6:16:13 AM
Certified Delivered
Security Checked
12/7/2022 5:17:29 AM
Signing Complete
Security Checked
12/7/2022 5:17:34 AM
Completed
Security Checked
12/7/2022 5:17:34 AM
Payment Events
Status
Timestamps
Electronic Record and Signature Disclosure


CONSENT TO ELECTRONIC DELIVERY AND EXECUTION OF DOCUMENTS  
From time to time, IQVIA (“we” or “us”) may provide you certain written contracts, notices, 
disclosures, authorizations, acknowledgements or other documents (collectively, the 
"Documents") electronically. Please read this consent form carefully. It explains the terms and 
conditions under which such Documents are provided by us and executed by you electronically 
through your DocuSign, Inc. (“DocuSign”) user account. If you consent to the delivery and 
execution of such Documents electronically, please click the "I Agree" button.  
Documents will be sent to you electronically  
If you consent to electronic delivery, Documents will be sent to your DocuSign user account. 
You may request a paper copy of documents previously made available through your DocuSign 
user account, but an additional charge may be incurred. Alternatively, you can download and 
print documents sent to your DocuSign user account. Unless otherwise noted, you can access a 
Document up to 30 days from the date we first sent the Document to you.  
Withhold Consent or Withdrawing Consent to Electronic Delivery  
If you withhold consent to electronic delivery or execution, or withdraw your consent at a later 
date, all Documents will be sent to your mailing address following our receipt of notice of such 
action. The following sections explain the consequences of withholding or withdrawing your 
consent to electronic delivery and execution of Documents, and also the procedures you must 
follow in order to effectuate delivery to your mailing address.  
Consequences of Withdrawing Consent  
By electing to only receive and execute Documents sent to your mailing address, we will not be 
able to carry out transactions or services as efficiently. For instance, some transactions or 
services require your express consent. We can perform these transaction or services only if we 
first receive an acknowledgement that indicates you received and consent to the Document 
related to the proposed transaction or service.  
To withhold consent now or withdraw consent at a later date, please sign DocuSign's "Withdraw 
Consent" form on the signing page of your DocuSign user account. This will indicate that you 
have withdrawn your consent to receive Documents electronically. Once you sign the "Withdraw 
Consent" form, you will no longer be able to use your DocuSign user account to execute 
Documents electronically and we will send Documents to your mailing address. Withdrawal of 
consent does not affect the validity of any Documents previously executed electronically prior to 
such withdrawal of Consent. In addition, should you execute any Documents electronically, your 
execution of such Documents shall indicate your continued consent to execute such Documents 
electronically.  
How to contact IQVIA:  
If you would like us to send the Documents to a different e-mail address, request paper copies of 
Documents you have previously received electronically, or withdraw your consent to receive 
electronic documents, please follow the instructions below. If you have any other questions, 
please contact: DocuSignSupport@IQVIA.com  
1. To advise IQVIA of your new e-mail address  
If you would like your Documents sent to a different e-mail address, you must send an e-mail 
message to DocuSignSupport@IQVIA.com . In the body of the e-mail please state the following: 
(i) your previous e-mail address, and (ii) your new e-mail address. No other information is 
required.  
!   !"   " ! 	  		 

!  !	  #  !    "!


In addition, you must notify DocuSign of your new e-mail address. Please log into your 
DocuSign user account, and follow the instructions to update your e-mail address.  
2. To request paper copies from IQVIA  
To request paper copies of Documents you have received previously through your DocuSign 
user account, send an e-mail to DocuSignSupport@IQVIA.com  
In the body of the e-mail please state the following: (i) your e-mail address, (ii) full name, (iii) 
U.S. Postal address, and (iv) telephone number. Additional charges may apply for such paper 
copies. 
3. To withdraw your consent with IQVIA  
To withdraw your consent to receiving and executing Documents in an electronic format, you 
may do one of the following: 
i. decline to sign a document from within your DocuSign user account, and on the 
subsequent page, select the check-box indicating you wish to withdraw your consent; or  
ii. send us an e-mail to DocuSignSupport@IQVIA.com and in the body of such request 
you must state your e-mail, full name, US Postal Address, telephone number, and account 
number. No additional information is necessary.  
Required hardware and software  
Operating Systems: Windows® 2000, Windows® XP, Windows Vista®; Mac OS® X 
Browsers: 
x  Internet Explorer (Windows Only) 8.0 or above – compatibility mode is 
supported only for 9.0 and above.  
x  Windows Edge Current Version  
x  Mozilla Firefox Current Version  
x  Safari (Mac OS only) 6.2 or above  
x  Google Chrome Current Version  
PDF Reader: 
Acrobat® or similar software may be required to view and print PDF files 
Screen Resolution: 
1024 x 768 Recommended  
Enabled Security 
Settings: 
Allow per session cookies 
Mobile Signing: 
x  Apple iOS 7.0 or above  
x  Android 4.0 or above  
** These minimum requirements are subject to change. If these requirements change, we will 
provide you with an e-mail message at the e-mail address we have on file for you at the time the 
hardware and software requirements are revised.  
Pre-release (e.g. beta) versions of operating systems and browsers are not supported.  
Acknowledging your access and consent to receive materials electronically  
To confirm you can access this information electronically and that you consent to receiving and 
executing Documents electronically on the terms and conditions described above, please let us 
know by clicking the "I Agree" button.  
By clicking the "I Agree" button, you confirm that  


x 
You can access and read this Consent To Electronic Delivery and Execution of 
Documents; and  
x 
You can print on paper the disclosure or save or send the disclosure to a place where you 
can print it, for future reference and access; and  
x 
Until or unless you notify IQVIA as described above, you consent to the delivery and 
execution of Documents electronically.